| D.C. Vaccine Conference Attracts Government Policy Makers and Key Biotech Developers | | Print | |
| Written by Staff and Wire Reports | |||||||||||||||||||||||||||||
| Sunday, 08 November 2009 00:00 | |||||||||||||||||||||||||||||
|
Several government officials, including representatives from the United States Department of Health and Human Services, National Research Council of Canada, National Institutes of Health, National Institute of Allergy and Infectious Disease, and the Food and Drug Administration, come together at this conference with with representatives from several key biotech and pharmaceutical companies to provide a first-hand reference of the current U.S. vaccines policy and regulations and updates on pandemic and bio-defense policies. Attendees will gather to discuss the most recent advancements in novel vaccines designed to target infectious disease like Influenza and AIDS, and will also attempt to gain ideas to use vaccines to target non-infectious diseases such as cancer and allergies.
Scheduled to present the event's opening remarks and to moderate several of the key presentation sessions is Dr.Daniel Zimmerman, Ph.D., (recently interviewed exclusively by BioMedReports), Senior Vice President Research and Development, Cellular Immunology for CEL-SCI Corporation (AMEX:CVM). Zimmerman's work at the company and in partnership with several research university partners has been attracting a great deal of attention in both the H1N1 influenza and inflammatory disease space lately. Companies who will share the spotlight in front of some of the key officials from the government agencies include: Ibis Biosciences, Inc.- In January of this year, this former subsidiary of Isis Pharmaceuticals, Inc. was acquired by Abbott (NYSE: ABT) for a total acquisition price of $215 million plus earn out payments.. The company develops, manufactures, and markets products for the identification and characterization of infectious agents. Immunovaccine, Inc. (CVE:IMV) a biotechnology company developing high potential vaccines for human health. Immunovaccine’s most advanced product is DPX-0907, a therapeutic vaccine against ovarian, breast and prostate cancer that, in conjunction with its vaccine delivery technology, is being readied to enter Phase 1 human clinical trials. The company will pursue a fast-track regulatory strategy by taking the product through a short Phase 1 into a Phase 2 clinical trial. In June, the company announced its intention to go public through an RTO transaction on the TSX-V exchange and with FDA approval for Phase I human clinical trial for ovarian, breast and prostate cancer vaccine to begin Q1 2010. Advaxis, Inc. (OTC:ADXS) a biotechnology company that uses a bioengineered bacterium, Listeria monocytogenes to activate the immune system to treat cancer, infectious disease or allergic syndromes. Unlike other therapeutic approaches, in pre-clinical research Advaxis’ Listeria technology has been able to consistently demonstrate complete therapeutic responses resulting in complete tumor regression. Preliminary results in humans have shown this technology to be safe, and the therapeutic outcomes are very encouraging. Advaxis is developing multiple platform approaches to the treatment of several cancers which represent a market potential in excess of $10 billion. EpiVax, a privately held company based in Providence, RI. dedicated to the development and implementation of computational immunology tools to benefit the biotechnology industry. VaxArt, a privately held biotech company based in San Francisco, CA. VaxDesign, a privately held biotech company based in Orlando, FL that develops in vitro models of human immunity that are functionally equivalent to the human immune system. The technologies help drug and vaccine development companies to obtain predictions of human outcomes for their therapies and have the potential to save companies years of development time and millions of dollars of development costs. At least three big pharmaceutical companies will also have representatives in attendance, including Novartis (NYSE:NVS), Sanofi Pasteur, and Merck (NYSE:MRK). Representatives from the academic research field will include: Dr. Kenneth S. Rosenthal, Ph.D., ProfessorMicrobiology/Immunology, Northeastern Ohio Universities Colleges of Medicine and Pharmacy Pirouz Daftarian, Head, Biological Modifiers Laboratory, University of Miami BiomedReports is not paid or compensated to report news and developments about publicly traded companies. Full disclosure can be read at the bottom of / About Us / Section Add this page to your favorite Social Bookmarking websites           
Set as favorite
Bookmark
Email this
Trackback(0)
Comments (9)
bernar
said:
|
On Monday and Tuesday of this week, the 7th Annual Vaccines: All Things Considered Conference is taking place in Washington, DC. Investors should keep an eye on this event, which serves as a one-stop destination for valuable updates and exposure on all aspects of vaccine research, development, regulations, and policy via key, intimate presentations by innovative biotech companies and government regulators.
TrackBack URI for this entry
Subscribe to this comment's feed|
... Good Evening, Is the public authorized to attend the conferance? If yes how do I get access and where is it located. Thank you, Bernard |
|
RCM
said:
|
... Didn't see Adam Feuerstein's name on the presenters list. Must have been inadvertently omitted. |
|
M.E.Garza
said:
|
... Not sure if the conference is public. Check with the organizers here: http://www.gtcbio.com/conferenceDetails.aspx?id=166 |
|
Tony Itwaru
said:
|
... RCM, Just for the record, Adam Fuerstein is currently occupied trying to figure out how long Johns Hopkins University Hospital has been in business and whether the operation is legit. At this moment he is conducting surveilance. If he isn't doing that... then he is probably weeping because he missed out on the bounce again and is writing his next 'masterpiece' to make the stock tumble once more.... |
|
Mambo
said:
|
... My Sources info was right on the Money on 11/06/09 we had a major development regarding World Famous John Hopkins University and what develops from this collobration will take CVM from $1.00 stock to a world recognized Bio tech company far more than $3.50 or even my Turkey day Target of $5.55, the validation of Leaps technology is game changer for CVM, CVM will be a double Digit Bio-tech company sooner than any of you Guys and gals can imagine, all of a sudden our Tiny little Bio-tech company is presenting at a major Conference in front of very important people that have the capability to fund multi million dollar grants to promote LEAPS and not to mention Giants of the pharmacutical companies. CVM price targets 2009/2010 and the reasons 1. $5.00+ by turkey day. 2. $7.00+ December 2009 3. $10.00+ March 2010. 4. $20.00++ December 2010 5. $30.00++ 2011 Reasons: 1. Major grants from federal government coming. 2. Major partnership announcement coming for LEAPS. 3. LEAPS stops Progression of H1N1 in matter of 24 Hrs announcement coming. 4. CVM state of the art plant validation by FDA coming soon. 5. Commencement of Multi Billion dollar cancer drug Mulkitene. 6. CVM LEAPS stops Rheumotidis Athritis, which is a multi Billion dollar Market. 7. LEAPS platform a major win for CVM, LEAPS effective against major immune related diseases. 8. Cvm will have a multi billion dollar generating Pipe line. 9. CVM a major take over target by a big bio-tech company, as major bio techs have patents expirations coming. 10. Finally, Cuz Mambo said so and you can Bank on it, If you have doubts go to HGSI board and see if my predictions were right:)$$$ |
|
RCM
said:
|
... Mambo, hope you are correct. Their success will make a significant difference in many lives (for many reasons). Tony, thanks for letting me know about Adam. I will sleep well tonight knowing he is safe. Dulce, thanks for your support! |
|
Tony Itwaru
said:
|
... Folks, if anyone out there is like me, a novice investor, then you should know that I personally think that MAMBO is a PUMPER. I love CVM and I am sure that everyone else who owns the stock feels the same, however, folks like MAMBO tend to inflate things for their own benefit and to your detriment. I was under the impression that BMR reviews these postings before they are put online, however, it appears not. I do think and hope that the stock will go up eventually but at the rate that MAMBO is predicting is more likely not going to happen. That said, invest with your head, NOT because MAMBO said so. MAMBO, if you are pumping, there is a place for you.... just go to thestreet.com. |
|
Write comment
